Similar articles

• As leukemia options grow, drugs jockey to be first-line therapies.

  Dolgin E. Dolgin E. Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7. Nat Med. 2013. PMID: 23295994 No abstract available.
• BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

  Schiffer CA. Schiffer CA. N Engl J Med. 2007 Jul 19;357(3):258-65. doi: 10.1056/NEJMct071828. N Engl J Med. 2007. PMID: 17634461 Review. No abstract available.
• Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].

  Kantarjian H. Kantarjian H. Clin Adv Hematol Oncol. 2008 Nov;6(11):797-9. Clin Adv Hematol Oncol. 2008. PMID: 19194361 No abstract available.
• Circumventing resistance to kinase-inhibitor therapy.

  Druker BJ. Druker BJ. N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073. N Engl J Med. 2006. PMID: 16775240 No abstract available.
• [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].

  Liu H, Chen XG. Liu H, et al. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17236546 Review. Chinese. No abstract available.